iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model.
Secured the effectiveness confirming data of PHAGERIA® technology for colorectal cancer organoids The first target cancer type of PHAGERIA® technology is colorectal cancer (CRC) BOSTON and SEOUL, South Korea, April 4, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today that iNtRON has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model. P18-BE3CRC is a...
Bridgewest Group completes acquisition of sterile injectable manufacturing plant in Western Australia from Pfizer
MIAMI and PERTH, Australia, April 4, 2023 /PRNewswire/ -- Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, announces that it has completed the acquisition of the Perth sterile injectable manufacturing facility from Pfizer (Perth) Pty Ltd, a subsidiary of Pfizer, Inc. Bridgewest...
BioDuro-Sundia Wins Life Sciences Review Top 10 BPO Award
IRVINE, Calif., April 4, 2023 /PRNewswire/ -- Life Sciences Review magazine recognizes BioDuro-Sundia as top 10 Business Process Outsourcing (BPO). BioDuro-Sundia earned this award for its high-quality service and cutting-edge technology, as well as its integrated contract research, development and manufacturing (CRDMO) service platforms. Dr. Kent Payne, CEO of BioDuro-Sundia, accepted the award. In an exclusive interview with Life Sciences...
Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects
HANGZHOU, China, April 4, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has recently completed phase I trials in healthy subjects in China for its self-developed innovative intestinal-restricted JAK inhibitor LNK01003. The results of the study showed good safety, tolerability, and pharmacokinetic performance. LNK01003 is...
AnPac Bio-Medical Science Enters into Asset Purchase Agreement with Easy Hundred Inc.
NEW YORK, April 3, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced that on March 31,...
GC Cell and New Management Embarking on a New Chapter
Securing future growth engine by scouting global talents; AGM resolved new CEO James Park and CTO Ho-won Kim as internal directors Setting business goals focusing on change and growth Proposing a new corporate vision of "Global Creator of Cell & Gene Therapy" YONGIN, South Korea, April 3, 2023 /PRNewswire/...
Harbour BioMed Reports Full Year 2022 Financial Results
CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 3, 2023 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, released annual results of full year 2022. "2022 has been our second financial year...
Perisai Paves the Way in Asia – Introducing Voice and Behavioral Risk Assessment for Insurance and Health Sectors.
SINGAPORE, April 3, 2023 /PRNewswire/ -- Voicesense and Bizbaz announce a new joint product called Perisai—Malay for Shield. Specifically designed for insurance, reinsurance, health and wellness companies, Perisai builds on the partners' existing cooperation in finance, e-commerce, mental health and fintech where they provide comprehensive customer intelligence and risk assessment capabilities in the Asia-Pacific region. For the first time in...
The World’s Second Approved Biosimilars of Denosumab (MAILISHU)
SHANGHAI, April 3, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that the Denosumab solution for injection (trade name: MAILISHU, project code: 9MW0311), which is developed by its wholly-owned subsidiary T-mab, has been formally approved for marketing by the National Medical Products Administration (NMPA) (Approval No.: S20233111). MAILISHU is the world's...
Tiens Group Attends Boao Forum for Asia Annual Conference 2023
Tiens focuses on global markets by engaging with likeminded peers from the four corners of the globe BOAO, China, April 3, 2023 /PRNewswire/ -- The highly anticipated Boao Forum for Asia (BFA) Annual Conference 2023 themed "An Uncertain World: Solidarity and Cooperation for Development amid Challenges", kicked off in Boao, China, on March 28-31. As a BFA senior platinum...
